

Division 55
Research Council Webpage

Articles to be Posted Under the Assigned Categories

Antipsychotics

- Correll, C.U., et al. (2020). "Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial." *JAMA Psychiatry*, 77(4): 349-358.
<https://doi.org/10.1001/jamapsychiatry.2019.4379>.
- Guinart, D. and Correll, C.U. (2020). "Antipsychotic Polypharmacy in Schizophrenia: Why Not?" *Journal of Clinical Psychiatry*, 81(3): 1-3.
<https://doi.org/10.4088/JCP.19ac13118>.

Drugs for the Treatment of Mood Disorders

- Jha, M.K. (2019). "Anti-inflammatory Treatments for Major Depressive Disorder: What's on the Horizon?" *Journal of Clinical Psychiatry*, 80(6): 1-3.
<https://doi.org/10.4088/JCP.18ac12630>.
- Viswanathan, M., et al. (2020). "Treatment of Depression in Children and Adolescents: A Systematic Review." Comparative Effectiveness Review No. 224. (Prepared by the RTI International–University of North Carolina at Chapel Hill Evidence-based Practice Center under Contract No. 290-2015-00011-I.) AHRQ Publication No. 20-EHC005-EF. Rockville, MD: *Agency for Healthcare Research and Quality*. <https://doi.org/10.23970/AHRQEPCCER224>.
- Lippard, E.T.C. and Nemeroff, C. (2020). "The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders." *American Journal of Psychiatry*, 177: 20–36.
<https://doi.org/10.1176/appi.ajp.2019.19010020>.
- D. Seftel and D. Boulware. [Prospective cohort of fluvoxamine for early treatment of COVID-19](#). *Open Forum Infectious Diseases*. Published online February 1, 2021. <https://doi.org/10.1093/ofid/ofab050>.
- E. Lenze et al. [Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19](#). *Journal of the American Medical Association*. Published online November 12, 2020. doi:10.1001/jama.2020.22760.

Anxiolytics / Sedatives

- Tseng, L-Y., et al. (2020). "Benzodiazepines, z-Hypnotics, and Risk of Dementia: Special Considerations of Half-Lives and Concomitant Use." *Neurotherapeutics*, 17: 156–164. <https://doi.org/10.1007/s13311-019-00801-9>.

Stimulants

Drugs for the Treatment of Substance Use Disorders

- Bahji, A., et al. (2020). "Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis." *JAMA Network Open*, 3(4): e202370. <https://doi.org/10.1001/jamanetworkopen.2020.2370>.
- Paulus, M.P. and Stewart, J.L. (2020). "Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review." *JAMA Psychiatry*. <https://doi.org/10.1001/jamapsychiatry.2020.0246>.

Other Drugs/Treatments

- Olmsted, K.L.R., et al. (2020). "Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial." *JAMA Psychiatry*, 77(2): 130-138. <https://doi.org/10.1001/jamapsychiatry.2019.3474>.
- Fink, H.A., et al. (2020). "Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia: A Systematic Review." Comparative Effectiveness Review No. 223. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290- 2015-00008-I.) AHRQ Publication No. 20-EHC003. Rockville, MD: *Agency for Healthcare Research and Quality*. <https://doi.org/10.23970/AHRQEPCCER223>.
- Davies, L.E., et al. (2020). "Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews." *Journal of the American Medical Directors Association*, 21: 181-187. <https://doi.org/10.1016/j.jamda.2019.10.022>.
- Tantisira, K. and Weiss, S.T. (2017). Overview of pharmacogenomics. *UpToDate*. <http://www.uptodate.com>. (Subscription required to access).
- Puzantian, T. and Carlat, D.J. (2020). *Medication Fact Book for Psychiatric Practice, 5th Edition*: Carlat Publishing, LLC, Newburyport, MA.
- Procyshyn, R.M., Bezchlibnyk-Butler, K.Z., and Jeffries, J.J. (2019). *Clinical Handbook of Psychotropic Drugs, 23rd Edition*: Hogrefe Publishing Corp., Boston, MA.

- Kothadia, R.J., Krause, M., and Atezaz Saeed, S. (2021). Pharmacologic management of autism spectrum disorder: A review of 7 studies. *Current Psychiatry*, 20 (01):33-38. <https://doi:10.12788/cp.0078>.
- D.E. Gordon et al. [Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms](#). *Science*. Vol. 370, December 4, 2020, p. eabe9403. DOI: 10.1126/science.abe9403.
- D.A. Rosen et al. [Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis](#). *Science Translational Medicine*. Vol. 11, February 6, 2019, p. eaau5266. Doi: 10.1126/scitranslmed.aau5266.

Articles by Division 55 Members

- McGrath, R. E. (2020). What is the right amount of training? Response to Robiner et al. *Clinical Psychology: Science and Practice*, 27(1), e12315. <https://doi.org/10.1111/cpsp.12315>
- Peck, K., McGrath, R. E., & Holbrook, B. B. (in press). Practices of prescribing psychologists: Replication and extension. *Professional Psychology: Research and Practice*.
- Ragusea, Anthony (2020) Adverse Drug Reactions: What Every Psychologist Should Know. *Journal of Health Service Psychology*, 46: 71-80. <https://doi.org/10.1007/s42843-020-00009-y>
- Moore, B.A., Pujol, L., Waltman, S., Shearer, D.S. (expected 2020). Management of post-traumatic stress disorder in veterans and military service members: A review of pharmacologic and psychotherapeutic interventions since 2016. *Current Psychiatry Reports*.
- Waltman, S.H., Shearer, D. S, & Moore, B.A. (2018). Management of Post-Traumatic Nightmares: A Review of Pharmacologic and Nonpharmacologic Treatments Since 2013. *Current Psychiatry Reports*, 20(12):108. doi: 10.1007/s11920-018-0971-2
- Shearer, D.S. (2019, April 26). WSPA endorses RxP: Results of a statewide survey. *Washington State Psychological Association (WSPA) News*. <http://wapsych-news.org/rxp-2019survey-results/>
- Shearer, D.S., Pujol, L., & Moore, B.A. (expected 2020). Prescribing psychologists in the Army: Primary care integration and tele-psychopharmacology. In B. Rom-Rymer (Ed). *Prescribing psychologists in the military: History, regulations, and cutting-edge practice*.

- Shearer, D.S., Brown, C.S., & Moore, B.A. (2018). Psychoses. In M. Muse (Ed), *Cognitive behavioral psychopharmacology: The clinical practice of biopsychosocial integration*. New York, John Wiley & Sons.
- Conway, E. (2020). A Primer on Precision Medicine: What Every Prescribing Psychologist Should Know. *Archives of Medical Psychology*, 11(1): 11-14.
- Brown, R. T., Abrahamson, D. J., Baker, D. C., Bevins, R. A., Grus, C. L., Hoover, M., LeVine, E. S., Lincoln, A. J., & Foster, E. O. (2020). The revised 2019 standards for psychopharmacological training: Model education and training program in psychopharmacology for prescriptive authority. *American Psychologist*. Advance online publication. <https://doi.org/10.1037/amp0000729>
- Preston, J.D., O'Neal, J.H., Talaga, M.C., and Moore, B.A. (2021). *Child and Adolescent Clinical Psychopharmacology Made Simple, 4th Edition*: New Harbinger's Publications, Inc., Oakland, CA.